Drug Profile
LCS 640
Alternative Names: LCS-640Latest Information Update: 18 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 18 Apr 2002 No development reported - Preclinical for Cancer in USA (unspecified route)
- 21 Sep 2000 New profile
- 21 Sep 2000 Preclinical development for Cancer in USA (Unknown route)